![]() |
|
![]() |
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
Sponsored by: |
Sirion Therapeutics, Inc. |
Information provided by: | Sirion Therapeutics, Inc. |
ClinicalTrials.gov Identifier: | NCT00549289 |
The purpose of this phase III, open-label study is to determine the safety and tolerability of cyclosporine in the treatment of dry eye syndrome.
Condition | Intervention | Phase |
Dry Eye Syndromes |
Drug: cyclosporine A |
Phase III |
ChemIDplus related topics: | Cyclosporine Cyclosporin |
Study Type: | Interventional |
Study Design: | Open Label, Single Group Assignment |
Ages Eligible for Study: | 2 Years and older |
Genders Eligible for Study: | Both |
Inclusion Criteria:
Exclusion Criteria:
Study ID Numbers: | ST-603-006 |
First Received: | October 24, 2007 |
Last Updated: | October 24, 2007 |
ClinicalTrials.gov Identifier: | NCT00549289 |
Health Authority: | United States: Food and Drug Administration |
|
|
|
|
![]() |